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Background.Theaimofthisstudywastodeterminecurrentcontraceptiveuse,contraceptivedesiresandknowledge,futurefertility
desires, and sterilization regret in a cohort of HIV-positive women. Study Design. 127 HIV-positive women receiving care at an
urban infectious disease clinic completed a survey addressing their contraceptive and reproductive histories as well as their future
contraceptiveandfertilitydesires.Results. Themostcommonformsofcontraceptionusedweresterilization(44.4%)andcondoms
(41.3%). Less than 1% used a long-term reversible method of contraception (LARC) despite these being the methods that best ﬁt
their desired attributes of a contraceptive method. Overall, 29.4% desired future fertility. Only 50.6% of those sexually active had
spoken with a provider within the last year regarding their contraceptive plans. There was a high degree of sterilization regret
(36.4%), and 18.2% of sterilized women desired future fertility. Multivariate analysis found women in a monogamous relationship
had a statistically increased rate of regret compared to women who were not sexually active (OR 13.8, 95% CI 1.6–119, P = 0.17).
Conclusion. Given the diversity in contraceptive and fertility desires, coupled with a higher rate of sterilization regret than is seen in
the general population, integration of comprehensive family planning services into HIV care via increased contraceptive education
and access is imperative.
1.Introduction
Since the mean desired fertility rate in the United States is
2[ 1], American women spend most of their reproductive
lives attempting to space or prevent pregnancies; however,
nearly half of all pregnancies in the USA are unintended
(unwanted or mistimed) [2]. Women at highest risk for
unintended pregnancies are also at highest risk for HIV
and sexually transmitted infection acquisition, including
women of minority race, lower education level, and lower
socioeconomic status [3]. Approximately 100,000 women
of reproductive age in the USA are infected with HIV, and
women of color disproportionately account for 80% of HIV-
infected women [4].
The prognosis for people living with HIV has greatly
improved and therefore the healthcare community is able
to focus on quality-of-life issues rather than only length of
life issues [5]. For example, the availability and use of highly
active antiretroviral therapy (HAART) has dramatically
reduced mother-to-child transmission and allowed HIV-
positive women to live longer, healthier lives which in turn
has aﬀected their fertility desires [6, 7]. Cohort studies of
HIV-positive women have noted a high use of sterilization
and a low use of hormonal contraception, despite desire for
future fertility [8, 9]. Reasons for low use of hormonal or
other eﬀective contraception were not explored.
Given their HIV status, often coupled with a lower socio-
economic status, these women represent a vulnerable cohort
in need of objective support in regards to their reproductive
choices. It remains unclear how advances in HIV therapy
have inﬂuenced HIV-positive women’s reproductive needs
and choices. Our study was designed to assess the contracep-
tive needs and fertility desires of an HIV-positive population
of women in order to help direct evidence-based, eﬀective,
integrated family planning services into the current HIV care
setting.2 Infectious Diseases in Obstetrics and Gynecology
2.MaterialandMethods
From December 2008 through January 2010, we recruited
a convenience sample of HIV-positive women presenting
to outpatient medical care at the Infectious Disease Clinic
associated with the Grady Health System in Atlanta, GA,
USA. This clinic provides care to a predominately urban and
underinsured population of HIV-positive men and women.
Inclusion criteria included females 18–50 years old, HIV-
positive, nonpregnant, and able to speak, read, understand,
and consent in English. Exclusion criteria included women
with uncontrolled psychiatric illness, unknown HIV status,
pregnancy, history of hysterectomy, or who were unable or
unwilling to consent to the study. The Institutional Review
Board at the Emory University and the Grady Research
Committee approved this study protocol, and all subjects
provided verbal informed consent.
Participants completed a self-administered, 35-question
written survey. To assure conﬁdentiality, surveys were com-
pleted in a private room beside the waiting area. The survey
inquired about the subject’s demographic characteristics,
obstetrical history, HIV medical history, most recent con-
traceptionusage,desiredcontraceptiveattributes,knowledge
of safety and availability of various contraceptives to HIV-
positive women, desire for future fertility, sterilization rates
and regret, and whether they have discussed their repro-
ductive choices/desires with their physician. Many of the
survey questions had been previously validated in other
reproductive healthcare surveys. Prior to study initiation,
the survey was piloted with 30 participants in the clinic to
assess the understandability and feasibility of administering
the survey instrument in this population.
2.1. Statistical Analysis. All statistical analyses were com-
pleted using SPSS version 17.0. Tests with P values <0.05
were considered statistically signiﬁcant. Outcomes of interest
included contraceptive use, desired contraceptive attributes,
contraceptive knowledge, future fertility desires, and steril-
ization regret. Descriptive statistics were generated. Contin-
uous variables were compared using Student’s t-test while
categorical variables were compared using Chi-square test.
Logistic regression was used to generate odds ratios and
95%conﬁdenceintervalsformultivariateanalysestoidentify
factors that were associated with sterilization regret and
future fertility desire.
3. Results
A total of 127 women were surveyed. The subjects had a
mean age of 37.8 years (standard deviation 8.4) with a range
18–50 years. The vast majority of subjects self-reported as
black (95%). Subjects’ educational background was diverse.
T h em a j o r i t yo fs u b j e c t s( 6 7 . 7 % )w e r eu n e m p l o y e d .M o s t
had been pregnant in the past (91.3%) and had borne
children (81.6%), and 37.3% of subjects had 4 or more prior
pregnancies. Nearly half (47.2%) were in a monogamous
relationship, and 27.6% were not currently in a sexual
relationship. The majority (60.6%) reported always using
condoms when they had sex. Nearly half (49.6%) of the
Table 1: Demographics.
Number Valid %
Age
18–25 13 10.2%
26–35 32 25.2%
36–45 58 45.7%
46–50 24 18.9%
Ethnicity
Black 120 94.5%
Hispanic 1 0.8%
White 4 3.1%
Other 1 3.1%
Missing 1
Education
Did not complete high school 48 37.8%
Completed high school/GED 39 30.7%
At least some college of technical school 32 25.2%
Completed college or above 8 6.3%
Missing 1
Reproductive history
Gravida 1 or more 115 91.3%
Para 1 or more 102 81.6%
Missing 2
Sexual relationship
Monogamous 60 47.2%
Non-monogamous 10 7.9%
Not currently sexually active 35 27.6%
Not sure 17 13.4%
Missing 5
HIV history
Diagnosed <5 years ago 34 28.8%
Diagnosed 5–10 years ago 27 21.3%
Diagnosed >10 years ago 63 49.6%
AIDS diagnosis 52 40.9%
Currently taking HAART 96 75.6%
women surveyed had been diagnosed with HIV for greater
than 10 years, and 28.8% reported being diagnosed less than
5 years. Overall, 40.9% had been diagnosed with AIDS and
75.6% were currently taking antiretroviral medications as
prescribed (Table 1).
3.1. Contraceptive Use and Desires. When asked to state
the last contraceptive method used, most women reported
using female sterilization (44.4%) or condoms (41.3%), with
only 24.4% using any type of hormonal method, and less
than 1% using long-term reversible contraception (LARC)
deﬁned as an IUD or implant (Table 2). While less than
60% of women knew about each of the LARC methods,
the most common methods subjects stated they wished to
learnmore about werethe LARC methods and the Nuvaring.
Most (91.3%) thought condoms were safe for HIV-positive
women; however, less than half of the participants thoughtInfectious Diseases in Obstetrics and Gynecology 3
Table 2: Last contraceptive method used.
Method Number∗ Percentage
Sterilization 56 44.4%
Condoms 52 41.3%
Depo-Provera 20 15.9%
Abstinence 8 6.3%
None 8 6.3%
Pill 7 5.6%
Patch 3 2.4%
Withdrawal 2 1.6%
∗n = 126, 1 missing.
Overall, 0.8% each used IUD, diaphragm, or cervical cap, NuvaRing, and
natural family planning.
Table 3: Contraceptive methods HIV-positive subjects have heard
of/think are safe to use.
Method Have heard of number Think are safe number
(%) (%)
Condoms 115 (92.7%) 115 (91.3%)
Pill 114 (91.6%) 55 (43.7%)
Sterilization 112 (90.3%) 41 (32.5%)
Depo-Provera 112 (90.3%) 46 (36.5%)
Patch 93 (75.0%) 30 (23.8%)
Abstinence 77 (62.1%) 78 (61.9%)
Implant 72 (58.1%) 23 (18.3%)
IUD 68 (54.8%) 26 (20.6%)
Diaphragm 65 (52.4%) 28 (22.2%)
Withdrawal 61 (49.2%) 28 (22.2%)
Plan B 54 (43.5%) 22 (17.5%)
Nuvaring 51 (41.4%) 23 (18.3%)
Missing 3 1
the pill, Depo-Provera, the patch, the IUD, the Nuvaring, or
implant were safe (Table 3).
Subjects were asked how satisﬁed they were with their
current contraceptive method: 58.1% were very satisﬁed,
17.9% were somewhat satisﬁed, and 23.9% were somewhat
or not at all satisﬁed. When asked to choose the three most
important factors to them when choosing a birth control
method, the most frequently cited attribute was ease of use,
followed by eﬃcacy at preventing pregnancy, and low risk of
side eﬀects (Table 4). Subgroup analyses of contraceptive use
and desires in women ≤45 years of age were not signiﬁcantly
diﬀerent with the exception that knowledge of sterilization
was lower (76.0% versus 90.3%, P = 0.005).
3.2.DesireforFertilityandDiscussionwithProviders. Overall,
29.4% of those surveyed desired future fertility. Of these
almost half (46.0%) were unsure of when they desired to
become pregnant in the future, and only 8.1% desired to
become pregnant within the next year. The factor most
strongly correlated with future fertility desire was age.
Univariate analysis found that women with greater than
4 prior live births were signiﬁcantly less likely to desire
Table 4: Most important attributes of contraceptive method
(women were asked to pick their top 3 attributes).
Attribute Number∗ Percentage
Easy to use 80 64.5%
Works well at preventing pregnancy 50 40.3%
Low in side eﬀects 44 35.5%
Low in cost 41 33.1%
Decreases menstrual cycles 31 24.8%
Works on the long term 25 20.2%
Maintains regular menstrual cycles 24 19.4%
Decreases period symptoms 22 17.7%
Quickly reversible 10 8.1%
Hormone-free 8 6.5%
No action required during sex 4 3.2%
∗n = 124, 3 missing.
future pregnancy; however, when controlling for age, this
association was no longer signiﬁcant. In a multivariate
model looking at predictors of future fertility desire, age
was found to be signiﬁcantly associated (OR 1.17, 95%
CI 1.08–1.26, P<0.001) with younger age associated
with increased fertility desire. In addition, women not
currently in a relationship were signiﬁcantly less likely to
desire future fertility compared to women in a monogamous
relationship (OR 0.26, 95% CI 0.09–0.77, P = 0.015). In
multivariate analyses, education, reproductive history, HIV
history, having a diagnosis of AIDS, or using HAART was
not associated with future fertility desire. Only 50.6% of
those sexually active had spoken with a provider in the past
year regarding their contraceptive plans. Approximately one-
third (32.1%) reported that they had either never spoken to
a provider or it was greater than 5 years ago.
3.3. Female Sterilization. The mean age of sterilization was
28 years of age with a range 21–39 years. More than half
(56.4%) reported that HIV/AIDS was one of the reasons
they chose to be sterilized. Sterilization regret was reported
in 36.4%, and 18.2% of these women desired to become
pregnant in the future. Multivariate analysis looking at age,
education, reproductive history, sexual relationship, HIV
history, AIDS diagnosis, and use of HAART medication
found that women in a monogamous relationship had a
statistically increased rate of regret compared to women who
were not sexually active (OR 13.8, 95% CI 1.6–119, P =
0.017). Age at sterilization and reporting that HIV/AIDS
was a factor in deciding to become sterilized were not
signiﬁcantly associated with regret.
4. Discussion
Our sample represented an older reproductive-aged, pre-
dominantly black and parous, urban, underinsured cohort,
with a high percentage functioning with a long-term diag-
nosis of HIV. Female sterilization was the most commonly
used form of contraception in our subjects (44.4%). Massad
et al. reported 23% use of sterilization, 30% use of barrier4 Infectious Diseases in Obstetrics and Gynecology
methods, and less than 10% use of hormonal methods
among US HIV-positive women in a 2007 study [8]. The
increased rate of sterilization we found may be related to
the characteristics of our cohort as it is similar to the 46.4
rate reported in age-comparable samples of the general
US population [10]. Although a substantial number of
these HIV-positive women had undergone sterilization, their
contraceptive and fertility desires suggest that eﬀective,
reversible contraceptive methods are more suitable.
Only 22.9% of subjects were using any type of hormonal
method, and less than 1% used long-term reversible con-
traception (LARC). Again, this is similar to age-comparable
rates of method use reported in the general population
[10]. This may be in part due to the fact that less than
half of the subjects thought the pill or Depo-Provera was
safe for HIV-positive women to use and less than a quarter
thought the LARC methods were safe. Concern in the
literature exists regarding hormonal contraceptive use in
women with HIV. Several studies of hormonal contraceptive
use in HIV-positive women have indicated an association
with increased shedding of HIV-1 DNA in the genital
tract, HIV acquisition and transmission, or clinical disease
progression [11–14]. However, multiple other studies have
failed to demonstrate a link between contraceptive use
and HIV-1 acquisition, transmission, and progression [15–
18]. The World Health Organization (WHO) in February
2012 concluded, upon the strength of the epidemiological
evidence and analysis of risks and beneﬁts to country
programmes, that no restrictions (MEC category 1) be
placed on the use of any hormonal contraceptive method
for women living with HIV [19]. In addition, based on
systematic reviews of all available literature, the Centers
for Disease Control USA Medical Eligibility Criteria (MEC)
for Contraceptive Use classiﬁes all hormonal and LARC
methods as acceptable for use (category 1 or 2) in HIV-
positive women. Information regarding medical eligibility
for all contraceptive methods in women with HIV/AIDS is
available at http://www.cdc.gov/reproductivehealth/usmec.
Although small studies have noted decreased hormonal
levels in the plasma of women using certain classes of
antiretrovirals, there is no evidence that this leads to an
increase in contraceptive failure in this population. The USA
Department of Health and Human Services recommends
additional or alternative (nonoral hormonal) contracep-
tion for HIV-infected women taking most nonnucleoside
reverse-transcriptase inhibitors or protease inhibitors and
recommends avoiding coadministering combined OCs with
fosamprenavir [20]. Alternatively, Depo-Provera was found
to have no interactions with several antiretroviral agents
[21, 22]. Consistent use of condoms in addition to hormonal
contraceptives is strongly recommended to prevent HIV
transmission and in addition may compensate for any
potential reduction in eﬃcacy or increased viral shedding
with hormonal contraceptives. Our results suggest that
additional patient counseling is required to educate HIV-
infected women regarding their risks as they appeared to
underestimate the safety proﬁle of most eﬀective, reversible
contraceptive methods.
When asked which attributes the subjects most desired
from their contraceptive method, they chose ease of use,
eﬀectiveness, and low risk of side eﬀects. Given these
factors, it is not surprising that so many subjects chose
female sterilization; however, given the substantial rate of
sterilization regret, the most suitable methods appeared to
be LARC methods. Like sterilization, the LARC methods
(progestin-only IUD, copper IUD, and the progestin-only
implant) are all rated as having “top tier eﬃcacy” per the
World Health Organization because they have a typical-
use failure rate of less than 1% [23]. Also like sterilization,
typical-use failure rates of LARC methods are comparable to
their perfect-use failure rates because little action is required
by the user. Because LARC provides either the lowest hor-
monal levels (progestin-only IUD, progestin-only implant)
or no hormones, they have low side eﬀect proﬁles and few
contraindications to use. Per The US Medical Eligibility
Criteria for Contraceptive Use, even women with AIDS can
have implants placed (category 1) and may have IUDs placed
with close followup or if no other method is available or
acceptable (category 2 or 3). Perhaps most important to
this population, the reversibility of LARC enables the use of
highlyeﬀectivecontraceptionwithouttheriskofsterilization
regret. The World Health Organization and the American
Congress of Obstetricians and Gynecologist (ACOG) state
that intrauterine devices (IUDs) are a safe contraceptive
method for HIV-infected women [4].
Of the women in the study who had been sterilized,
one-third (36.4%) regretted their sterilization, and 18.2%
reported they desired children in the future. Stanwood et al.
found similar rates of HIV-positive women sterilized (47%)
and wanting children after sterilization (12%) [9]. However,
the United States Collaborative Review of Sterilization found
an overall rate of sterilization regret of 7.5% at 7 years in
the general population [24]. It is also interesting that in our
sample, an additional 18.2% stated they regret their tubal
sterilization although they do not currently desire future
fertility. A prior systematic review evaluating age and risk
of sterilization regret found that women under 30 were
about twice as likely as those over 30 to express regret [25].
Our ﬁndings were not consistent with this; however, we did
ﬁnd that women currently in a monogamous relationship
had statistically higher rates of regrets than those not in a
relationship. Future relationship status may be a much more
diﬃcult factor to foresee preoperatively than one’s age as a
predictor of future regret. Nevertheless, our results indicate
the need for more in-depth preprocedure counseling in an
attempt to decrease the rate of regret in this population.
The relatively high rates of tubal ligation and of tubal
regret in our population highlight the importance of our
need to counsel HIV-positive women on highly eﬀective
reversible contraceptive methods, especially as they are
greatly underused and yet appear to suit their contraceptive
desires. It also highlights the importance of screening them
regarding their future fertility desires. ACOG currently rec-
ommends that reproductive plans, including preconception
counseling and counseling regarding reversible methods
of contraception, should be discussed with HIV-infected
women of childbearing age [4].Infectious Diseases in Obstetrics and Gynecology 5
Our study has the following limitations. As this survey
included sensitive topics, social desirability and stigma may
have biased respondents’ answers. Our study population
received care in an academic, urban setting and therefore
may not be generalizable to all HIV-positive women in
care. As this was a cross-sectional study, we can only make
ﬁndings of associations, not deﬁnitive conclusions on cause
and eﬀect.
5. Conclusions and Implications
Women acquiring HIV through heterosexual relationships
are currently the largest growing group of HIV-positive
patients. Given current therapies, this population is living
longer, healthier lives with access to HIV care. Therefore it
is important that providers ask HIV-positive women about
their reproductive needs and discuss contraception and STI
prevention as part of their routine care. Based on our results
this population is most commonly using sterilization for
contraception despite an unfortunately high level of regret.
In addition, this population is under-using LARCs despite
these being the type of method they most desire. It is
important that providers ask HIV-positive women about
their reproductive needs and desires, discuss contraception,
and provide preconception counseling if appropriate. There
has been little progress integrating family planning services
and HIV/AIDS care. Often clinic staﬀ views family planning
and HIV prevention as independent services and are not
trained to administer them together [26]. Governments and
funding agencies have a growing awareness of the need to
address the reproductive choices of HIV-positive women and
agree that HIV/STI and family planning services should be
integrated [27, 28]. Partnerships between HIV/AIDS services
and family planning services may be more responsive to the
needs of reproductive-age HIV-positive women and may be
more likely to provide complete, high-quality care.
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